Long Term Follow-up Grafted Huntington's Disease Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

39 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-01-01

Study Completion Date

2034-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Long-term follow-up of Huntington's disease patients treated with intrastriatal allografts is essential to assess the benefit/risk ratio of grafts as well as their effectiveness. Indeed, some patients are likely to develop adverse effects and the impact of alloimmunisation phenomena remains to be explored.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

MIG-HD: Multicentric Intracerebral Grafting in Huntington's Disease

NCT00190450

Huntington Disease

COMPLETED PHASE2

Deep Brain Stimulation Treatment for Chorea in Huntington's Disease

NCT04244513

Huntington Disease Deep Brain Stimulation

UNKNOWN NA

Deep Brain Stimulation of the Globus Pallidus in Huntington's Disease

NCT00902889

Huntington's Disease

COMPLETED PHASE1

Deep Brain Stimulation (DBS) of the Globus Pallidus (GP) in Huntington's Disease (HD)

NCT02535884

Huntington Disease

COMPLETED NA

Beta Testing of a New Assessment in Huntington's Disease (HD)

NCT03119246

Huntington Disease

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The aim is to create a specific cohort of transplant patients, to homogenise their follow-up methods, to collect all the patient data (medical, paramedical, imaging, biological) acquired from the end of their participation in MIG-HD'study (Foetal Striatal allografting in Huntington's disease: a multicentre, randomised, delayed start, phase 2 open-label cell therapy trial) until the last possible follow-up of the last patient in the study

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Huntington Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Long term follow-up

* Formalized and standardized follow-up
* Retrospective data collection
* Biological collections
* Biological collections's centralisation

Group Type OTHER

Follow-up

Intervention Type OTHER

Follow-up grafted patients as long as their condition allows

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Follow-up

Follow-up grafted patients as long as their condition allows

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patients transplanted under the MIG-HD protocol
* Information and informed consent from patients or their representative
* Affiliation with a social security scheme or beneficiary